Tap1-KO Mouse
一般名
Tap1-KO
製品ID
S-KO-19084
背景情報
C57BL/6JCya
系統ID
KOCMP-21354-Tap1-B6J-VB
状況
このマウス系統を論文で使用する場合は、「Tap1-KO Mouse(カタログ番号S-KO-19084)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Tap1-KO
系統ID
KOCMP-21354-Tap1-B6J-VB
遺伝子名
製品ID
S-KO-19084
遺伝子別名
Y3, TAP, APT1, Ham1, MTP1, PSF1, ABC17, Abcb2, Ham-1, RING4, Tap-1
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 17
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000170086
NCBIトランスクリプトID
NM_013683
ターゲット領域
Exon 4~5
有効領域の大きさ
~1.7 kb
遺伝子研究の概要
Tap1, also known as Antigen Peptide Transporter 1, is a member of the ATP-binding cassette (ABC) family. It is crucial for transporting antigen peptides from the cytoplasm to the lumen of the endoplasmic reticulum, and then loading them onto major histocompatibility complex (MHC) class I molecules, thus playing a significant role in the immune response and antigen presentation [5].
Tap1 has been associated with multiple diseases. In ankylosing spondylitis, specific polymorphisms in Tap1 (Tap1-333Val, Tap1-637Gly) were likely to be associated with the disease, especially when compared with HLA-B27-negative controls [1]. In uveal melanoma, upregulated Tap1 was associated with shorter survival, higher metastasis likelihood, and higher mortality, and in vitro silencing of Tap1 inhibited cell proliferation and metastasis [2]. In gastric cancer, Tap1 was identified as a T-cell related therapeutic target, and oxaliplatin could enhance immunotherapy by promoting Tap1 expression [3]. In colorectal cancer, down-regulation of Tap1 was a mechanism of tumor immune escape and a poor prognostic factor [4]. In pancreatic cancer, Tap1 promoted resistance to MEK inhibitors, and suppressing Tap1 sensitized resistant cells to the inhibitor [6]. In gastric carcinoma, TAP1 expression was positively correlated with various immunological traits and patients with high TAP1 expression were more likely to achieve complete remission after immunotherapy [5]. In locally advanced gastric cancer, high Tap1 expression was associated with better overall survival [7]. In a study with Apoe⁻/⁻Tap1⁻/⁻ mice, Tap1-deficiency did not alter atherosclerosis development, indicating a minor role for CD8⁺ T cells and Tap1-dependent antigen presentation in this disease process [8].
In conclusion, Tap1 is essential for antigen presentation and immune response. Studies, especially those using gene-knockout mouse models like Apoe⁻/⁻Tap1⁻/⁻ mice, have revealed its diverse roles in multiple diseases, including autoimmune diseases, cancers, and atherosclerosis. These findings contribute to a better understanding of disease mechanisms and may provide potential therapeutic targets.
References:
1. Qian, Yufeng, Wang, Genlin, Xue, Feng, Tang, Liang, Yang, Huilin. 2017. Genetic association between TAP1 and TAP2 polymorphisms and ankylosing spondylitis: a systematic review and meta-analysis. In Inflammation research : official journal of the European Histamine Research Society ... [et al.], 66, 653-661. doi:10.1007/s00011-017-1047-1. https://pubmed.ncbi.nlm.nih.gov/28405734/
2. Zhu, Ru, Chen, Yu-Ting, Wang, Bo-Wen, Jiang, Fa-Gang, Zhang, Ming-Chang. 2023. TAP1, a potential immune-related prognosis biomarker with functional significance in uveal melanoma. In BMC cancer, 23, 146. doi:10.1186/s12885-023-10527-9. https://pubmed.ncbi.nlm.nih.gov/36774490/
3. Zhao, Yupeng, Liu, Ziyuan, Deng, Kaiyuan, Li, Ranran, Xia, Jiazeng. 2024. Identification of TAP1 as a T-cell related therapeutic target in gastric cancer by mediating oxalipliatin-related synergistic enhancement of immunotherapy. In International immunopharmacology, 132, 111998. doi:10.1016/j.intimp.2024.111998. https://pubmed.ncbi.nlm.nih.gov/38593510/
4. Ling, Agnes, Löfgren-Burström, Anna, Larsson, Pär, Edin, Sofia, Palmqvist, Richard. 2017. TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer. In Oncoimmunology, 6, e1356143. doi:10.1080/2162402X.2017.1356143. https://pubmed.ncbi.nlm.nih.gov/29147604/
5. He, Zehua, Yang, Hong, Chen, Qingfeng, He, Wanrong, Chen, Zhihui. 2024. Role of TAP1 in the identification of immune-hot tumor microenvironment and its prognostic significance for immunotherapeutic efficacy in gastric carcinoma. In Journal of gastrointestinal oncology, 15, 890-907. doi:10.21037/jgo-24-28. https://pubmed.ncbi.nlm.nih.gov/38989426/
6. Li, Boya, Feng, Yu, Hou, Qiaoyun, Fu, Yan, Luo, Yongzhang. 2022. Antigen Peptide Transporter 1 (TAP1) Promotes Resistance to MEK Inhibitors in Pancreatic Cancers. In International journal of molecular sciences, 23, . doi:10.3390/ijms23137168. https://pubmed.ncbi.nlm.nih.gov/35806187/
7. Segami, Kenki, Aoyama, Toru, Hiroshima, Yukihiko, Saeki, Hiroshi, Oshima, Takashi. . Clinical Significance of TAP1 and DLL4 Expression in Patients With Locally Advanced Gastric Cancer. In In vivo (Athens, Greece), 35, 2771-2777. doi:10.21873/invivo.12562. https://pubmed.ncbi.nlm.nih.gov/34410967/
8. Kolbus, Daniel, Ljungcrantz, Irena, Söderberg, Ingrid, Nilsson, Jan, Fredrikson, Gunilla Nordin. 2012. TAP1-deficiency does not alter atherosclerosis development in Apoe-/- mice. In PloS one, 7, e33932. doi:10.1371/journal.pone.0033932. https://pubmed.ncbi.nlm.nih.gov/22479479/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
